Provided by Tiger Trade Technology Pte. Ltd.

Nutriband Inc.

4.25
-0.1899-4.28%
Volume:8.58K
Turnover:36.72K
Market Cap:51.74M
PE:-1.40
High:4.42
Open:4.33
Low:4.25
Close:4.44
52wk High:11.68
52wk Low:3.96
Shares:12.17M
Float Shares:3.90M
Volume Ratio:0.75
T/O Rate:0.22%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.0405
EPS(LYR):-0.9882
ROE:-136.08%
ROA:-55.22%
PB:6.86
PE(LYR):-4.30

Loading ...

Company Profile

Company Name:
Nutriband Inc.
Exchange:
NASDAQ
Establishment Date:
2016
Employees:
- -
Office Location:
121 South Orange Avenue,Suite 1500,Orlando,Florida,United States
Zip Code:
32801
Fax:
- -
Introduction:
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops AVERSA buprenorphine and AVERSA methylphenidate, and other transdermal pharmaceutical products. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

Directors

Name
Position
Gareth Sheridan
Chief Executive Officer and Director
Serguei Melnik
Chairman of the Board, President and Secretary
Mark Hamilton
Independent Director
Irina Gram
Director
Radu Bujoreanu
Director
Sergei Glinka
Director
Stefani Mancas
Director

Shareholders

Name
Position
Gareth Sheridan
Chief Executive Officer and Director
Alan Smith
Chief Operating Officer and President of 4P Therapeutics
Gerald Goodman
Chief Accounting Officer and Chief Financial Officer
Jeff Patrick
Chief Scientific Officer
Serguei Melnik
Chairman of the Board, President and Secretary